13F Holdings
中文EN

LSTA LISATA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 320017 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-90.7%
TTM net income YoY5.9%
TTM EPS YoY11.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-22,043.0%
Net margin-17,159.0%
FCF margin-21,662.0%
EBITDA margin-22,020.0%

Returns

ROE-137.2%
ROA-5.1%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets8.8%
Debt / equity0.00x
Current ratio14.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.26x
Accruals ratio1.3%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$170,000$1.00M$0$0—
R&D expense$7.95M$11.33M$12.73M$13.07M$17.58M
SG&A expense$10.43M$12.07M$12.97M$14.14M$11.47M
Operating income-$18.21M-$22.41M-$25.71M-$57.60M-$29.05M
Pretax income-$17.55M-$20.78M-$23.17M-$56.70M-$28.97M
Income tax-$962,000-$798,000-$2.33M-$2.48M-$1.51M
Net income-$16.59M-$19.98M-$20.84M-$54.23M-$27.47M
EBITDA-$18.06M-$22.23M-$25.52M-$57.53M-$29.00M
EPS (basic)-1.91-2.40-2.58-10.47-7.45
EPS (diluted)-1.91-2.40-2.58-10.47-7.45
Weighted avg. shares (diluted)8.69M8.33M8.07M5.18M3.69M
Balance sheet
Cash & equivalents$15.96M$16.21M$22.59M$32.15M$24.65M
Receivables$0$900,000$0——
Current assets$17.70M$34.58M$53.92M$71.88M$96.18M
PP&E, net$18,000$72,000$175,000$296,000$62,000
Goodwill$0————
Intangibles$0$192,000$263,000$334,000$0
Total assets$17.74M$35.00M$54.69M$73.03M$97.01M
Current liabilities$3.07M$5.61M$6.59M$6.38M$4.52M
Total liabilities$3.14M$5.68M$6.80M$6.71M$5.01M
Shareholders' equity$14.86M$29.57M$48.15M$66.58M$92.25M
Shares outstanding8.83M8.41M8.15M7.87M3.99M
Cash flow statement
Operating cash flow-$15.95M-$19.36M-$20.03M-$21.17M-$22.25M
Capital expenditure$28,000$0$0$285,000$60,000
Free cash flow-$15.98M-$19.36M-$20.03M-$21.45M-$22.30M
Investing cash flow$15.09M$13.23M$10.10M$28.91M-$54.90M
Financing cash flow$599,000-$206,000$385,000-$224,000$85.28M
Depreciation & amortization$146,000$174,000$189,000$69,000$55,000
Stock-based compensation$1.23M$1.65M$2.04M$2.64M$2.00M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.